1. State-of-the-art non-targeted metabolomics in the study of chronic kidney disease
- Author
-
Nathalie Neirynck, Koen Sandra, Eva Schepers, Raymond Vanholder, Pat Sandra, Griet Glorieux, Frederic Lynen, Ruben t'Kindt, Lucie Jorge, and Jente Boelaert
- Subjects
Creatinine ,Chromatography ,Endocrinology, Diabetes and Metabolism ,Clinical Biochemistry ,Renal function ,Pharmacology ,medicine.disease ,Biochemistry ,chemistry.chemical_compound ,Metabolomics ,Blood serum ,chemistry ,Liquid chromatography–mass spectrometry ,Metabolome ,medicine ,Biomarker (medicine) ,Kidney disease - Abstract
Here we report a metabolomics discovery study conducted on blood serum samples of patients in different stages of chronic kidney disease (CKD). Metabolites were monitored on a quality controlled holistic platform combining reversed-phase liquid chromatography coupled to high-resolution quadrupole time-of-flight mass spectrometry in both negative and positive ionization mode and gas chromatography coupled to quadrupole mass spectrometry. A substantial portion of the serum metabolome was thereby covered. Eighty-five metabolites were shown to evolve with CKD progression of which 43 metabolites were a confirmation of earlier reported uremic retention solutes and/or uremic toxins. Thirty-one unique metabolites were revealed which were increasing significantly throughout CKD progression, by a factor surpassing the level observed for creatinine, the currently used biomarker for kidney function. Additionally, 11 unique metabolites showed a decreasing trend.
- Published
- 2013